Table 2. Psoriatic arthritis treatment regimen at clinic visit (n=961).
| Treatment | n | % |
| Monotherapy with any csDMARD | 407 | 42 |
| Methotrexate | 295 | 31 |
| Sulfasalazine | 62 | 6 |
| Leflunomide | 42 | 4 |
| Hydroxychloroquine | 4 | 0.4 |
| Cyclosporine | 4 | 0.4 |
| Combination with one or more csDMARD | 94 | 10 |
| Monotherapy with any bDMARD | 221 | 23 |
| Adalimumab | 73 | 8 |
| Etanercept | 49 | 5 |
| Infliximab | 35 | 4 |
| Golimumab | 22 | 2 |
| Certolizumab pegol | 26 | 3 |
| Ustekinumab | 10 | 1 |
| Secukinumab | 6 | 1 |
| Combination bDMARD with one or more csDMARD | 100 | 10 |
| csDMARD: Conventional synthetic disease-modifying antirheumatic drug; bDMARD: Biological disease-modifying antirheumatic drug. | ||